首页> 美国卫生研究院文献>Journal of Clinical Oncology >Low-Dose Interleukin-2 Immunotherapy Does Not Improve Outcome of Patients Age 60 Years and Older With Acute Myeloid Leukemia in First Complete Remission: Cancer and Leukemia Group B Study 9720

【2h】

Low-Dose Interleukin-2 Immunotherapy Does Not Improve Outcome of Patients Age 60 Years and Older With Acute Myeloid Leukemia in First Complete Remission: Cancer and Leukemia Group B Study 9720

机译：低剂量白细胞介素2免疫疗法不能改善首次完全缓解的60岁及以上急性髓样白血病患者的治疗效果：癌症和白血病B组研究9720

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

PurposeCancer and Leukemia Group B (CALGB) 9720 evaluated subcutaneous low-dose recombinant interleukin-2 (rIL-2) maintenance immunotherapy as a strategy for prolonging remission in older patients with acute myeloid leukemia (AML).

机译：目的癌症和白血病B组（CALGB）9720评估了皮下低剂量重组白介素2（rIL-2）维持免疫疗法作为延长老年急性髓性白血病（AML）患者缓解的策略。

著录项

期刊名称 Journal of Clinical Oncology
作者
Maria R. Baer; Stephen L. George; Michael A. Caligiuri; Ben L. Sanford; Sandra M. Bothun; Krzysztof Mrózek; Jonathan E. Kolitz; Bayard L. Powell; Joseph O. Moore; Richard M. Stone; John Anastasi; Clara D. Bloomfield; Richard A. Larson;
展开▼
作者单位

展开▼
年(卷),期 -1(26),30
年度 -1
页码 4934–4939
总页数 6
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. [J] . Baer MR, George SL, Caligiuri MA, Journal of Clinical Oncology . 2008,第30期

机译：低剂量白细胞介素2免疫疗法不能改善首次完全缓解的60岁及以上的急性髓样白血病患者的预后：癌症和白血病B组研究9720。
2. Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808. [J] . Jonathan E Kolitz, Stephen L George, Don M Benson, Cancer: A Journal of the American Cancer Society . 2014,第7期

机译：首次完全缓解的60岁以下急性髓性白血病患者中的重组白细胞介素2：来自癌症和白血病B组19808的结果。
3. Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808. [J] . Jonathan E Kolitz, Stephen L George, Don M Benson, Cancer: A Journal of the American Cancer Society . 2014,第7期

机译：重组白细胞介素-2在60岁以下患者急性髓性白血病患者的患者，癌症和白血病B组19808年的结果。
4. Identification of Platelet Factor-4 as an Indicator of Blood Count Recovery in Acute Myeloid Leukemia Patients in Complete Remission [C] . Jin Young Kim, Ho-Jun Song, Hoi-Jeong Lim, ASMS Conference on Mass Spectrometry and Allied Topics . 2008

机译：血小板因子-4的鉴定为急性髓性白血病患者血统恢复的指标完全缓解
5. Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study [D] . Harada Yasuhiko, 原田靖彦 2019

机译：根据2017年日本成人白血病研究组（JALSG）AML201研究治疗的成人急性髓性白血病患者的遗传学预测，根据2017 ELN风险分层进行预后分析
6. Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720 [O] . MR Baer, SL George, BL Sanford, -1

机译：60岁及以上的急性髓性白血病患者的ADE方案中的Daunorubicin升级和添加依托钠：癌症和白血病组研究9720
7. Low-Dose Interleukin-2 Immunotherapy Does Not Improve Outcome of Patients Age 60 Years and Older With Acute Myeloid Leukemia in First Complete Remission: Cancer and Leukemia Group B Study 9720 [O] . Baer, Maria R., George, Stephen L., Caligiuri, Michael A., 2008

机译：低剂量白细胞介素2免疫疗法不能改善首次完全缓解的60岁及以上急性髓样白血病患者的治疗效果：癌症和白血病B组研究9720

Low-Dose Interleukin-2 Immunotherapy Does Not Improve Outcome of Patients Age 60 Years and Older With Acute Myeloid Leukemia in First Complete Remission: Cancer and Leukemia Group B Study 9720

摘要

著录项

相似文献

相关主题

期刊订阅